FIELD: chemistry.
SUBSTANCE: present invention relates to biotechnology and provides humanised synthetic analogues (R6313/G2) of variable domains of the anti-angiotensin II type 1 receptor monoclonal scFv antibody 6313/G2, i.e. which specifically bind the molecule which specifically binds with a peptide, having the amino acid sequence EDGIKRIQDD. The invention also discloses a method of treating cancer, use of specifically binding molecules according to the invention when preparing a drug for treating cancer, a combined preparation and pharmaceutical compositions containing a specifically binding molecule according to the invention and angiotensin II.
EFFECT: present invention enables to block the harmful effect of angiotensin II and use said analogues to treat cancer in humans.
9 cl, 15 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HUMAN ANNEXIN A1 ANTIBODY | 2011 |
|
RU2596403C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| ILT7 BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2756109C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| MOLECULES WHICH BIND TO PSL PSEUDOMONAS, AND METHODS FOR USE THEREOF | 2012 |
|
RU2708977C2 |
| IL-6 ANTAGONISTS AND USES THEREOF | 2013 |
|
RU2670943C9 |
| METHODS OF COMBINED THERAPY USING BINDING MATERIALS WITH PSL AND PCRV PSEUDOMONAS | 2012 |
|
RU2687588C2 |
